Clinical Trials Directory

Trials / Completed

CompletedNCT00002000

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
—
Sponsor
Glaxo Wellcome · Industry
Sex
All
Age
13 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).

Detailed description

Efficacy variables include the length of the episode, the time to lesion healing, the duration and severity of pain/discomfort, the duration of viral shedding, the proportion of patients with aborted episodes, the proportion of patients requiring extended therapy.

Conditions

Interventions

TypeNameDescription
DRUGValacyclovir hydrochloride
DRUGAcyclovir

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

22 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00002000. Inclusion in this directory is not an endorsement.